BACKGROUND Activation of coagulation and thrombus formation were considered as the initial steps in the mechanism of arterial restenotic reaction, which could be potential targets for action of drug eluting stent. Initial animal studies suggested that local delivery of direct thrombin inhibitor, argatroban, suppressed platelet aggregation and smooth muscle cell proliferation after balloon angioplasty. Furthermore, several human trials of local delivery of this drug demonstrated significant reduction of angiographic restenosis rates. Accordingly, argatoroban-eluting stent (JF-04) was developed, which composed of cobalt-chromium thin strut (70mm) stent platform, carrier biodegradable polymer (50:50 poly DL-lactide-co-glycolide), and argatroban. Drug elution was designed to complete within 40 days, whereas polymer remained up to 9 months. The objective of this firstin-man study was to test the safety and feasibility of the JF-04 stent to treat coronary lesions.
METHODS A total of 31 patients with either stable angina or unstable angina, or silent myocardial ischemia, who had de novo coronary lesions (legion length: 6 -26 mm, reference diameter: 2.5 -3.5 mm by visual estimation) were enrolled in the 7 Japanese sites. The lesions were treated with the JF-04 stent after pre-dilatation. The primary endpoint was set as angiographic in-stent late loss at 6-month after implantation. The secondary endpoints consisted of angiographic, intravascular ultrasound (IVUS), and optical coherence tomography (OCT) representative parameters at 6-month and clinical outcomes at 9-month. Major adverse cardiac events (MACE) were defined as composites of cardiac death, any myocardial infarction, and target vessel revascularization (TVR). Dual antiplatelet therapy was mandated at least for 6-month after implantation.
RESULTS
Procedural success was achieved in 100%. Angiographic instent late loss was 1.01 AE 0.48 mm and binary restenosis rate (insegment) was 29.0%. Other representative angiographic, IVUS, and OCT parameters are summarized in CONCLUSIONS The first-in-man study of biodegradable polymerbased argatroban-eluting stent failed to show sufficient inhibition of neointimal hyperplasia in de novo native coronary lesions, which resulted in relatively high restenosis rate as well as advanced angiographic restenotic patterns. Estimated potential mechanisms of these unfavorable outcomes included 1) limited capability inherent to argatroban for inhibition of cellular proliferation and 2) an unignorable gap in duration of elution/ absorption between drug and polymer. RESULTS A total of 1,293 (71.7%) patients were treated for complex coronary lesions, while 455 (25.1%) patients were treated for multiple target lesions. The 3-year incidence of TVF (primary endpoint) and various secondary endpoints will be reported for both DES groups, including the individual components of the primary endpoint. In addition, the incidence of stent thrombosis, the composite endpoint target lesion failure, and the more patient-oriented composite clinical endpoints major adverse cardiac events and patient-oriented composite endpoint will be presented.
